Malignancy validation in a United States registry of rheumatoid arthritis patients

BMC Musculoskeletal Disorders

Volumn 13, Issue , 2012, Pages

  Fisher, Mark C ^a   Furer, Victoria ^b   Hochberg, Marc C ^c   Greenberg, Jeffrey D ^d   Kremer, Joel M ^d   Curtis, Jeff R ^e   Reed, George ^f   Harrold, Leslie ^f   Solomon, Daniel H ^g  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NYU HOSPITAL FOR JOINT DISEASES   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d STATE UNIVERSITY OF NEW YORK   (United States)

^e University of Alabama at Birmingham   (United States)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Malignancy; Registry; Rheumatoid arthritis; Validation

Indexed keywords

ADULT; ADVERSE OUTCOME; ARTICLE; DISEASE REGISTRY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DOCUMENTATION; MEDICAL RECORD; PREDICTIVE VALUE; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; AGED; CLASSIFICATION; COMORBIDITY; DRUG SURVEILLANCE PROGRAM; INCIDENCE; MIDDLE AGED; NEOPLASM; REGISTER; REPRODUCIBILITY; UNITED STATES; VALIDATION STUDY;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ARTHRITIS, RHEUMATOID; COMORBIDITY; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; REGISTRIES; REPRODUCIBILITY OF RESULTS; UNITED STATES;

EID: 84861585483     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-13-85     Document Type: Article

References (24)

1. Cash JM, Klippel JH: Second-line drug therapy for rheumatoid arthritis. N Engl J Med 1994, 330:13681375.
2. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, Hoover R, Fraumeni JF Jr: Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993, 85:307311.
3. Biancone L, Calabrese E, Petruzziello C, Pallone F: Treatment with biologic therapies and the risk of cancer in patients with IBD. Nat Clin Pract Gastroenterol Hepatol 2007, 4:7891.
4. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:22752285.
5. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM: Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002, 46:31513158.
6. Kanik KS, Cash JM: Does methotrexate increase the risk of infection or malignancy? Rheum Dis Clin N Am 1997, 23:955967.
7. Askling J, Baecklund E, Granath F, Geborek P, Fored M, Backlin C, Bertilsson L, Coster L, Jacobsson LT, Lindblad S, et al: Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009, 68:648653.
8. Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, Sundstrom C, Bertilsson L, Coster L, Geborek P, et al: Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005, 64:14141420.
9. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, Coster L, Geborek P, Jacobsson LT, Lindblad S, et al: Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005, 64:14211426.
10. Chakravarty EF, Michaud K, Wolfe F: Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005, 32:21302135.
11. Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson IF, Saxne T, Olsson H, Jacobsson LT: Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005, 64:699703.
12. Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, Glynn RJ, Cook EF, Carney G, Schneeweiss S: Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:27572764.
13. Wolfe F, Michaud K: Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004, 50:17401751.
14. Wolfe F, Michaud K: Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007, 56:28862895.
15. Wolfe F, Michaud K: The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007, 56:14331439.
16. Amari W, Zeringue AL, McDonald JR, Caplan L, Eisen SA, Ranganathan P: Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology (Oxford), 50:14311439.
17. Khurana R, Wolf R, Berney S, Caldito G, Hayat S, Berney SM: Risk of development of lung cancer is increased in patients with rheumatoid arthritis: a large case control study in US veterans. J Rheumatol 2008, 35:17041708.
18. Parikh-Patel A, White RH, Allen M, Cress R: Risk of cancer among rheumatoid arthritis patients in California. Cancer Causes Control 2009, 20:10011010.
19. Kremer J: The CORRONA database. Ann Rheum Dis 2005, 64(Suppl 4):iv3741.
20. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R, et al: The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993, 36:729740.
21. Setoguchi S, Solomon DH, Glynn RJ, Cook EF, Levin R, Schneeweiss S: Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data. Cancer Causes Control 2007, 18:561569.
22. Ramsey SD, Scoggins JF, Blough DK, McDermott CL, Reyes CM: Sensitivity of administrative claims to identify incident cases of lung cancer: a comparison of 3 health plans. J Manag Care Pharm 2009, 15:659668.
23. Curtis JR, Jain A, Askling J, Bridges SL Jr, Carmona L, Dixon W, Finckh A, Hyrich K, Greenberg JD, Kremer J, et al: A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum 2010, 40:214 e11.
24. Kremer JM, Greenberg J: Interpreting registry-derived drug studies: does societal context matter? Arthritis Rheum 2009, 60:31553157.